While N-linked carbohydrate is known to comprise a significant portion of the mass of HIV-1 envelope protein, the dogma has been that O-linked carbohydrate is absent from HIV-1 envelope protein. The Desrosiers laboratory has now shown unambiguously that a subset of HIV-1 isolates have O-linked carbohydrate on the V1 region of their gp120 surface glycoprotein. Furthermore, this O-linked carbohydrate is able to shield virus from recognition by potent broadly-neutralizing antibodies of the V3-glycan class. Our results suggest that long V1 regions, sometimes with sometimes without O-linked glycosylation, can emerge as a mechanism to escape neutralizing antibodies similar to the V3-glycan monoclonal antibodies that have been defined to date. Our proposed studies will better define the characteristics of V1 region sequences that are predictive of whether an individual sequence is likely to be O-glycosylated. We will determine whether there is specificity to the blocking effects, i.e. whether one O-glycosylated V1 region potently blocks recognition by one V3-glycan mAb but not another while a different O-glycosylated V1 region may have different specificities to its blocking effects. We will use experimental SHIV infection of rhesus monkeys to examine whether there is selective disadvantage to such long O-glycosylated V1 regions in the absence of such antibodies and to examine the types of selective pressure that may drive elongation and O-glycosylation of V1 regions.

Public Health Relevance

The amazing collection of monoclonal antibodies with potent neutralizing activity against a broad range of HIV-1 isolates has stimulated great interest in their use for therapeutic and for prevention purposes, whether by passive administration or by long-term delivery with vectors such as adeno-associated virus. As use of such monoclonal antibodies in people increases, it will be important to understand the nature of different resistance mutations and the selective pressures driving certain types of sequence changes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI104523-07A1
Application #
10012154
Study Section
HIV Molecular Virology, Cell Biology, and Drug Development Study Section (HVCD)
Program Officer
Novak, Leia Kaye
Project Start
2013-02-15
Project End
2025-02-28
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Miami School of Medicine
Department
Pathology
Type
Schools of Medicine
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146
Termini, James M; Church, Elizabeth S; Silver, Zachary A et al. (2017) Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation. J Virol 91:
Postler, Thomas S; Pantry, Shara N; Desrosiers, Ronald C et al. (2017) Identification and characterization of a long non-coding RNA up-regulated during HIV-1 infection. Virology 511:30-39
Panico, Maria; Bouché, Laura; Binet, Daniel et al. (2016) Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding. Sci Rep 6:32956
Stansell, Elizabeth; Panico, Maria; Canis, Kevin et al. (2015) Gp120 on HIV-1 Virions Lacks O-Linked Carbohydrate. PLoS One 10:e0124784